Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,881 total articles
Oracle sits at the center of the AI infrastructure build-out with a reported $638B backlog, but the company is also burning cash to build capacity and has taken on meaningful leverage. The market appears to be pricing near-perfect execution. This trade idea outlines a disciplined short with a clear entry, stop and target over a long-term horizon (1…
Candel Therapeutics (CADL) is a clinical-stage viral immunotherapy company with late-stage assets and near-term commercialization plans for localized prostate cancer. The stock trades at a $720M market cap with an enterprise value around $573M, recently strengthened by a $100M offering. Positive Phase 3 signals and a clear cash runway make CADL a t…
Clearwater Paper (CLW) is trading at a steep discount to book and at bargain valuation multiples (EV/EBITDA ~6.2, P/B ~0.32). Near-term earnings and free cash flow are pressured, but tangible asset value and a manageable debt load give asymmetric upside over a 180-trading-day horizon. This trade idea outlines an actionable long entry at $15.93 with…
MediaAlpha (MAX) has taken a reputational hit from an FTC settlement and follow-on investigations, but the core business - programmatic lead generation for insurance carriers - earns solid cash flow and trades at undemanding revenue multiples. We outline a mid-term long trade that buys a recovery in insurance ad spend while keeping a disciplined st…
Fox Factory (FOXF) trades at $16.51 with a $692M market cap, attractive price-to-sales of 0.47 and EV/sales of 0.9. Operational strain and a negative EPS have crushed the equity, but free cash flow and a strong current ratio give the company runway. This trade idea outlines an actionable long with entry at $16.50, stop at $13.25 and a realistic tar…
dLocal (DLO) has seen a notable shift in market sentiment following its June 29, 2026 inclusion in the Russell indexes and consecutive quarters of very strong TPV and gross-profit growth. Technical momentum is bullish and liquidity is improving, creating a tactical long opportunity for traders willing to own the stock over the next several weeks. T…
Cardinal Health (CAH) is a defensive distributor with strong free cash flow, expanding end‑market exposure (radiopharma, automation) and a newly raised quarterly dividend. The shares trade near a 52‑week high but still offer an attractive free‑cash‑flow yield relative to market cap. We rate CAH a buy with a measured entry at $238.89, a stop at $217…
Mosaic (MOS) looks vulnerable to a near-term leg down after a trade announcement drives follow-through selling. Price sits below key moving averages, free cash flow is negative, and short activity is elevated. This is a tactical short for traders: entry $21.11, target $19.80, stop $22.50, horizon short term (10 trading days).
Republic Services (RSG) operates in a duopoly-like corner of the economy: low volatility revenue, strong free cash flow, and structural demand from population growth and regulation. At $217.35 today, the stock offers a practical swing trade that captures operational improvement and multiple expansion while protecting downside with a clear stop. Thi…
I am opening a mid-term long position in Bristow Group (VTOL) at $41.43. The company reported $388.7M in Q1 revenue, reaffirmed 2026 adjusted EBITDA guidance of $295-$325M, and trades at roughly a 10.7x P/E and ~5.3x EV/EBITDA. Operational cash flow and an improving government/defense backlog plus eVTOL partnerships set up asymmetric upside to a $5…
Frontier is a speculative buy around $7.50. The carrier has a low EV relative to sales, a clear strategy to move upmarket via ancillaries and higher-yield routes, and momentum in technicals. Offsetting that are weak liquidity, negative free cash flow, and elevated leverage. This trade is binary: buy size should be small, with a tight stop and a pla…
Meta is trading under $600 while its AI-focused capex and excess data-center capacity are beginning to produce measurable returns. Fundamentals (33% revenue growth cited in recent coverage, $48.25B free cash flow, 28.9% ROE) and a subdued valuation on a P/E of ~21 argue for a mid-term long trade. Enter on weakness; use a disciplined stop and a targ…
AMLP offers a compelling income angle — distributions that annualize near 7.9% based on the latest quarterly payment and a 30-day SEC yield around 5.6% — packaged in an ETF wrapper that investors often use to avoid K-1 headaches. That yield is attractive relative to many dividend ETFs, but AMLP brings concentration, fee drag, and energy-cycle sensi…
AST SpaceMobile has delivered technical milestones and locked telecom partnerships, but the stock is pricing a lot of future success today. If you can stomach volatility and are willing to wait, a disciplined long with a clear stop and a 180-trading-day horizon offers an asymmetric payoff: downside limited by a stop near recent support, upside tied…
CRISPR Therapeutics ($60.09) looks actionable after a pediatric expansion for Casgevy and renewed analyst optimism. The company is early-commercial with tiny revenue today but a deep cash cushion and several upcoming catalysts. Trade idea: initiate a long at $60.09, stop $48.00, target $90.00 with a mid-term horizon (45 trading days). Expect volati…
Ternium (TX) looks attractively priced at $41.77 with a market cap near $8.43B, P/B ~0.67 and a 5.3% dividend yield. Fundamentals are cyclical but stable: integrated steel and mining operations, improving short interest, and a 52-week range that leaves upside to the $51.73 high. This trade idea lays out an actionable long with an entry at $41.77, s…
Nvidia pulled back into the $190s after a recent run. Fundamentals - $4.78T market cap, 81.7% ROE, $119B free cash flow - still justify a premium. This trade targets a bounce back to the $240 area over the next 45 trading days with a disciplined $170 stop to limit downside.
Hims & Hers ($36.77) is carving out a breakout above multi-week resistance as technical momentum aligns with a strategic pivot: from high-margin GLP-1 compounding toward branded weight-loss distribution, international scale via the Eucalyptus acquisition, and product diversification. This trade buys that the market is beginning to re-rate HIMS as a…
American Electric Power (AEP) is a classic infrastructure beneficiary of the AI data-center boom. With the largest U.S. transmission system, $75.4B market cap, a $78B five-year capital plan and 63 GW of contracted load by 2030, AEP offers steady earnings growth, a 2.7% yield, and near-term momentum. This trade idea buys AEP for long-term upside whi…
Grifois is trading near its 52-week low after a period of operational disruptions and regulatory scrutiny. With a market cap of $6.32B, a P/E of ~10x, PB under 1x, and improving volume trends, the risk/reward now favors taking a tactically sized long position. This trade idea lays out entry, stop, targets, catalysts, and the specific horizon (180 t…
Kymera Therapeutics is a clinical-stage leader in small-molecule targeted protein degradation (TPD). With Phase 1/1b data showing deep target engagement for KT-621, multiple upcoming proof-of-concept readouts through 2027, a $1.6B cash runway into 2029, and a market cap of roughly $9.38B, Kymera looks set for near-term re-rating. This article lays …
SK Hynix's decision to list in the U.S. is more than a secondary share offering - it materially expands the company's investor base, improves price discovery, and creates a structural catalyst for the memory industry. I recommend a long trade for patient investors looking to play a potential re-rating and improved M&A optionality over the next 180 …
KLA's inspection and metrology franchise offers more stable leverage to advanced packaging and AI-driven fab demand than lithography alone. With $4.0B in free cash flow, an 80% ROE and recent guidance tailwinds, KLA presents a tactical long with defined risk controls versus larger, more concentrated peers.
Monopar (MNPR) has closed the informational gap that left investors guessing about ALXN1840's clinical impact. Recent Phase 2 and Phase 3 readouts, an NDA submission on track for mid-2026, and a healthy cash runway tilt the risk-reward toward upside. This trade idea lays out an actionable long: entry at $97.50, stop at $80.00, target $145.00, with …
Lucid Diagnostics (LUCD) trades like a binary healthcare small cap: modest commercial traction, tight liquidity, and heavy short interest. A clearance or favorable Medicare coverage decision for its reflux-to-cancer screening test would likely re-rate the stock; absent that, the company faces cash burn and dilution risk. This trade idea offers a co…
